A surviving patient after a cumulative dose of 250 g of cyclophosphamide

Scand J Rheumatol. 2015;44(6):520-1. doi: 10.3109/03009742.2015.1054878. Epub 2015 Aug 20.

Authors

R Mercan¹, B Bitik², Ö Ekinci³, B Goker²

Affiliations

¹ a Internal Medicine, Department of Rheumatology , Antakya Hospital , Hatay.
² b Department of Internal Medicine, Division of Rheumatology , Gazi University Hospital , Ankara , Turkey.
³ c Department of Pathology , Gazi University Hospital , Ankara , Turkey.

PMID: 26291486
DOI: 10.3109/03009742.2015.1054878

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Administration, Oral
Arthritis, Rheumatoid / drug therapy*
Cyclophosphamide / administration & dosage
Cyclophosphamide / adverse effects*
Cyclophosphamide / therapeutic use
Dose-Response Relationship, Drug
Female
Humans
Middle Aged
Scleritis / chemically induced*
Scleritis / diagnosis
Withholding Treatment

Substances

Cyclophosphamide